Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Traws Pharma Inc

TRAW ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$0.42

▼ -6.56%

Market Cap $6.39M · Vol 7.29K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.39M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

-130.01%

YoY

RSI (14)

39.09

Momentum

Beta

1.58

vs Market

52W High

$3.23

87.12% below

52W Low

$0.42

0.24% above

Volume

7.29K

Avg 38.49K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

86.65%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Traws Pharma Inc (TRAW) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TRAW pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-22.39%

-26.28%

-45.26%

-71.89%

YTD

-63.19%

-86.18%

-97.52%

-99.55%

Financials & Valuation

TTM · Annual

Total Revenue	$2.79M
Net Income	$9.17M
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-640.68%
Net Profit Margin	328.67%
ROE	N/A
ROA · ROIC	51.55% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	0.01
P/S	3.39
P/B	N/A
P/FCF	N/A
EPS Growth	-130.01%
Outstanding Shares	15.37M

Technical Indicators

50-Day SMA	$0.54
200-Day SMA	$1.23
RSI (14)	39.09
Beta	1.58
52-Week High	$3.23
52-Week Low	$0.42

Volume Today	7.29K
Avg Daily Volume (30D)	38.49K
Relative Volume	0.19x
Volatility (10D)	84.32
Volatility (30D)	75.96
Free Float	86.65%

Analyst Consensus

HOLD

Current Price $0.42

Mean Target $1.00

52W Low$0.42 52W High$3.23

Current

Target

$0.42 $3.23

Current Analyst target

+140.38% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001T921M7

ISINUS68232V8845

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.31% ONC BeOne Medicines AG -1.15% 068270.KS Celltrion, Inc. +0.45% MEDP Medpace Holdings, Inc. +1.31% ABVX Abivax SA -1.37%

Company Profile

Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.